Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of neratinib plus capecitabine for HER2-positive advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma with brain metastases
CTR20241419Phase 2Active
- Sponsor
- Convalife Pharmaceutical
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib, capecitabine in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, sponsored by Convalife Pharmaceutical. Started Apr 2024; status: active.
02
Drugs
neratinibcapecitabine
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on CTR20241419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241419.